Related Experiment Video

Updated: Jul 29, 2026

Dynamic Imaging of Chimeric Antigen Receptor T Cells with [18F]Tetrafluoroborate Positron Emission Tomography/Computed Tomography
09:34

Dynamic Imaging of Chimeric Antigen Receptor T Cells with [18F]Tetrafluoroborate Positron Emission Tomography/Computed Tomography

Published on: February 17, 2022

3.7K

Recent updates on CAR T clinical trials for multiple myeloma

Quande Lin1, Juanjuan Zhao1, Yongping Song1

  • 1The Affiliated Cancer Hospital of Zhengzhou University and Henan Cancer Hospital, 127 Dongming Road, Zhengzhou, 450008, China.

Molecular Cancer
|November 6, 2019
PubMed

Insights

Chimeric antigen receptor (CAR) T-cell therapies show promise for relapsed or refractory multiple myeloma (MM). Ongoing clinical trials are evaluating CAR T-cells targeting various antigens for improved MM treatment outcomes.

Area of Science:

  • Hematology
  • Immunology
  • Oncology

Background:

  • Multiple myeloma (MM) treatments, including proteasome inhibitors and monoclonal antibodies, have improved outcomes but relapse remains common.
  • Refractory/relapsed (RR) MM patients have limited therapeutic options.
  • Chimeric antigen receptor (CAR) T-cell therapy is an emerging treatment modality for hematologic malignancies.

Purpose of the Study:

  • To review recent advancements in CAR T-cell clinical trials for multiple myeloma.
  • To summarize ongoing research and development of CAR T-cell therapies targeting various antigens in RRMM.

Main Methods:

  • Review of ongoing clinical trials for CAR T-cell therapy in multiple myeloma.
  • Analysis of CAR T-cell strategies targeting B cell maturation antigen (BCMA), CD138, CS1 glycoprotein antigen (SLAMF7), light chains, and CD19.
  • Inclusion of studies on dual-target CAR T-cells and combination therapies.

Main Results:

  • CAR T-cells targeting BCMA, CD138, SLAMF7, and light chains are under active investigation for RRMM.
  • CD19-targeted CAR T-cells combined with autologous stem cell transplantation demonstrate activity in RRMM.
  • Dual-target CAR T-cells are being evaluated in clinical trials for RRMM.

Conclusions:

  • CAR T-cell therapy represents a promising frontier in the treatment of refractory/relapsed multiple myeloma.
  • Ongoing clinical trials are exploring novel CAR T-cell targets and strategies to overcome treatment resistance and improve patient outcomes in MM.
  • Further research and clinical evaluation are essential to establish the full potential of CAR T-cells in MM management.
Keywords:
B cell maturation antigenBCMACAR TChimeric antigen receptorMultiple myeloma

More Related Videos

Intracranial Cannula Implantation for Serial Locoregional Chimeric Antigen Receptor CAR T Cell Infusions in Mice05:22

Intracranial Cannula Implantation for Serial Locoregional Chimeric Antigen Receptor CAR T Cell Infusions in Mice

Published on: February 24, 2023

4.1K
Studying Interactions between Myeloid Cells and CAR T Cells In Vitro and In Vivo05:14

Studying Interactions between Myeloid Cells and CAR T Cells In Vitro and In Vivo

Published on: July 25, 2025

686

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Cancer Therapies02:49

Cancer Therapies

Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
Treatment Resistent Cancers02:56

Treatment Resistent Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
Clinical Trials01:16

Clinical Trials

Clinical trials are prospective experimental studies conducted on humans to determine the safety and efficacy of treatments, drugs, diet methods, and medical devices. Using statistics in clinical trials enables researchers to derive reasonable and accurate conclusions from the collected data, allowing them to make wise decisions in uncertain situations. In medical research, statistical methods are crucial for preventing errors and bias.
There are four phases in a clinical trial. A phase one...
Clinical Trials: Overview01:11

Clinical Trials: Overview

Clinical development focuses on how the drug will interact with the human body and encompasses four key phases of clinical trials, each serving a specific purpose in assessing the safety and effectiveness of new drugs. These phases overlap and build upon one another. Phase I involves a small group of healthy volunteers (typically 20-80 individuals) or, in cases where significant toxicity is expected, patients with the targeted disease, such as cancer or AIDS. The volunteers are tested for...
Tumor Immunotherapy01:27

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.